Engineering a Camelid Antibody Fragment That Binds to the Active Site of Human Lysozyme and Inhibits Its Conversion into Amyloid Fibrils
Authors:
- Pak-Ho ChanPak-Ho Chan
- Els PardonEls Pardon
- Linda MenzerLMLinda Menzer
- Erwin De GenstEGErwin De Genst
- Janet R. KumitaJKJanet R. Kumita
- John ChristodoulouJCJohn Christodoulou
- Dirk SaerensDirk Saerens
- Alain BransABAlain Brans
- Fabrice BouillenneFBFabrice Bouillenne
- David B. ArcherDADavid B. Archer
- Carol V. RobinsonCarol V. Robinson
- Serge MuyldermansSerge Muyldermans
- 25 September 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 47 (42) , 11041-11054
Abstract
A single-domain fragment, cAb-HuL22, of a camelid heavy-chain antibody specific for the active site of human lysozyme has been generated, and its effects on the properties of the I56T and D67H amyloidogenic variants of human lysozyme, which are associated with a form of systemic amyloidosis, have been investigated by a wide range of biophysical techniques. Pulse-labeling hydrogen−deuterium exchange experiments monitored by mass spectrometry reveal that binding of the antibody fragment strongly inhibits the locally cooperative unfolding of the I56T and D67H variants and restores their global cooperativity to that characteristic of the wild-type protein. The antibody fragment was, however, not stable enough under the conditions used to explore its ability to perturb the aggregation behavior of the lysozyme amyloidogenic variants. We therefore engineered a more stable version of cAb-HuL22 by adding a disulfide bridge between the two β-sheets in the hydrophobic core of the protein. The binding of this engineered antibody fragment to the amyloidogenic variants of lysozyme inhibited their aggregation into fibrils. These findings support the premise that the reduction in global cooperativity caused by the pathogenic mutations in the lysozyme gene is the determining feature underlying their amyloidogenicity. These observations indicate further that molecular targeting of enzyme active sites, and of protein binding sites in general, is an effective strategy for inhibiting or preventing the aberrant self-assembly process that is often a consequence of protein mutation and the origin of pathogenicity. Moreover, this work further demonstrates the unique properties of camelid single-domain antibody fragments as structural probes for studying the mechanism of aggregation and as potential inhibitors of fibril formation.Keywords
This publication has 46 references indexed in Scilit:
- Stabilization of an Immunoglobulin Fold Domain by an Engineered Disulfide Bond at the Buried Hydrophobic RegionJournal of Biological Chemistry, 2007
- Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain AntibodiesJournal of Molecular Biology, 2005
- Rationalising Lysozyme Amyloidosis: Insights from the Structure and Solution Dynamics of T70N LysozymeJournal of Molecular Biology, 2005
- Kinetic Stabilization of the Native State by Protein Engineering: Implications for Inhibition of Transthyretin AmyloidogenesisJournal of Molecular Biology, 2005
- Reduced Global Cooperativity is a Common Feature Underlying the Amyloidogenicity of Pathogenic Lysozyme MutationsJournal of Molecular Biology, 2005
- Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolutionJournal of Molecular Medicine, 2003
- β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the CamelidaeAntimicrobial Agents and Chemotherapy, 2001
- Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodiesJournal of Molecular Recognition, 1999
- MOLMOL: A program for display and analysis of macromolecular structuresJournal of Molecular Graphics, 1996
- Characterization of Conformational Preferences in a Partly Folded Protein by Heteronuclear NMR Spectroscopy: Assignment and Secondary Structure Analysis of Hen Egg-White Lysozyme in TrifluoroethanolBiochemistry, 1995